Molecular monitoring of imatinib in chronic myeloid leukemia patients in complete cytogenetic remission: does achievement of a stable major molecular response at …

C Pavlovsky, I Giere, B Moiraghi, MA Pavlovsky… - … Myeloma and Leukemia, 2011 - Elsevier
Background Monitoring minimal residual disease (MRD) by real-time quantitative
polymerase chain reaction (RT-PCR) in chronic myeloid leukemia (CML) patients is …
被引用次数：8 相关文章

Molecular Monitoring of Imatinib in Chronic Myeloid Leukemia Patients in Complete Cytogenetic Remission: Does Achievement of a Stable Major Molecular …

C Pavlovsky, I Giere, B Moiraghi… - Clinical Lymphoma …, 2011 - search.ebscohost.com
Background: Monitoring minimal residual disease (MRD) by real-time quantitative
polymerase chain reaction (RTPCR) in chronic myeloid leukemia (CML) patients is …

Molecular monitoring of imatinib in chronic myeloid leukemia patients in complete cytogenetic remission: does achievement of a stable major molecular response at …

C Pavlovsky, I Giere, B Moiraghi… - Clinical lymphoma …, 2011 - pubmed.ncbi.nlm.nih.gov
Background Monitoring minimal residual disease (MRD) by real-time quantitative
polymerase chain reaction (RT-PCR) in chronic myeloid leukemia (CML) patients is …

Molecular monitoring of imatinib in chronic myeloid leukemia patients in complete cytogenetic remission: does achievement of a stable major molecular response at …

C Pavlovsky, I Giere, B Moiraghi… - … Myeloma & Leukemia, 2011 - europepmc.org
Background Monitoring minimal residual disease (MRD) by real-time quantitative
polymerase chain reaction (RT-PCR) in chronic myeloid leukemia (CML) patients is …

Molecular Monitoring of Imatinib in Chronic Myeloid Leukemia Patients in Complete Cytogenetic Remission: Does Achievement of a Stable Major Molecular …

C Pavlovsky, I Giere, B Moiraghi, MA Pavlovsky… - … Myeloma and Leukemia, 2011 - infona.pl
Monitoring minimal residual disease (MRD) by real-time quantitative polymerase chain
reaction (RT-PCR) in chronic myeloid leukemia (CML) patients is mandatory in the era of …

[引用][C] Molecular monitoring of imatinib in chronic myeloid leukemia patients in complete cytogenetic remission: Does achievement of a stable major molecular …

C Pavlovsky, I Giere, B Moiraghi… - Clinical …, 2011 - produccioncientifica.ucm.es
Background: Monitoring minimal residual disease (MRD) by real-time quantitative
polymerase chain reaction (RT-PCR) in chronic myeloid leukemia (CML) patients is …

Molecular Monitoring of Imatinib in Chronic Myeloid Leukemia Patients in Complete Cytogenetic Remission: Does Achievement of a Stable Major Molecular …

C Pavlovsky, I Giere, B Moiraghi… - Clinical …, 2011 - clinical-lymphoma-myeloma …
Background Monitoring minimal residual disease (MRD) by real-time quantitative
polymerase chain reaction (RT-PCR) in chronic myeloid leukemia (CML) patients is …